California Watch
News stories in this section spotlight activities in California, including actions by the state Assembly and state Senate; proposed legislation; regulators like the Department of Managed Health Care and Department of Insurance; and the state ACA exchange, Covered California.
NPs and PAs have recently taken on a larger role in primary care. Health experts say those roles will help fill primary care gaps in the coming years with physician shortages expected.
CVS expects to close its $69 billion acquisition of Aetna after the Thanksgiving holiday.
Moving swiftly to fill the highest-ranking member of his nascent administration, Gov.-elect Gavin Newsom tapped Ann O’Leary, a longtime policy advisor to Hillary Clinton, to serve as his chief of staff and a leader of the transition team this fall.
Melissa Hurtado was confident she could unseat State Sen. Andy Vidak, R-Hanford.
What do hip-hop dancing and health insurance have in common?
During a yearslong examination of drug prices, there’s been no shortage of criticism for growing list prices, and in recent months, some companies have heard the talk and lowered their prices. Now, top PBM Express Scripts is rolling out a new formulary to help support the moves—and the plan could heap more pressure on players in competitive drug classes.
More than two weeks after announcing that the Obamacare website, HealthCare.gov, had been hacked, the Department of Health and Human Services has revealed that the breach exposed a wealth of information, including partial Social Security numbers and immigration status.
Healthcare has been a central theme of the 2018 election, arguably more so than any other election in recent history.
African Americans, Asians and Pacific Islanders living in California are just as likely to have health insurance as whites, marking a significant turnaround from five years ago, new data shows.
In a highly controversial move, the Food and Drug Administration approved an especially powerful opioid painkiller despite criticism that the medicine could be a “danger” to public health. And in doing so, the agency addressed wider regulatory thinking for endorsing such a medicine amid nationwide angst about overdoses and deaths attributed to opioids.